For a study, researchers sought to assess coronavirus disease 2019 (COVID-19)-related symptoms, risk factors for thrombosis, coagulation, and inflammatory parameters were evaluated in 145 previously healthy non-critically sick young people, with 29 patients reporting uncommon thrombotic events (UTEs) and 116 not experiencing thrombotic events. In patients with UTEs, inflammatory indices, coagulation, and the prothrombotic platelet phenotype (PTPP) were considerably greater than in those without. Patients with UTEs were divided into non-TG and TG sub cohorts based on the presence of thrombophilic genes (TGs), coagulation, and inflammatory markers. SVT, stroke, cerebral vein thrombosis, thrombotic microangiopathy, limb ischemia, inferior vena cava thrombosis (3 each), ST-segment elevation myocardial infarction, superior vena cava thrombosis, upper limb deep venous thrombosis, and retinal vein thrombosis (1 each) were among the 38.
Researchers discovered a 55% prevalence of TGs, primarily heterozygous coagulation factor II, thrombin (FII)-G20210A, Janus kinase 2 (JAK2)-V617F, protein-S, and antithrombin III deficiency, as well as a high (769%) prevalence of venous UTEs, multiple vessel thrombosis, and recurrence rate among the TG versus non-TG SVT, had been associated to the mutations JAK2-V617F and FII-G20210A. Thrombosis in the non-TG subcohort was associated with more hemorrhagic problems, thrombosis progression, and a significantly higher level of inflammatory markers, PTPP, mean platelet volume, von Willebrand factor, and factor VIII, all of which remained elevated for up to 6 months, as well as elevated D-dimer. Acquired and hereditary thrombophilia with epitheliopathy was found to be a significant mechanism to explain the prevalence of UTEs unrelated to COVID-19 severity.